Navigation Links
Published reports inaccurate concerning alcohol consumption during pregnancy
Date:12/19/2008

INDIANAPOLIS A national alcohol research group is concerned that the media's misinterpretation of a recent British research study could encourage pregnant women to be more at ease with temperate alcohol consumption.

Some media reports erroneously stated that the study by The University College London researchers revealed that light drinking by pregnant women could be beneficial to their babies. Other articles said light drinking during pregnancy would not affect the behavior or mental acuity of babies born to drinking mothers.

The Fetal Alcohol Spectrum Disorders Study Group, a subgroup of the Research Society on Alcoholism, says the conclusion of the study was not reported accurately. "Unfortunately, several media outlets misinterpreted this report to mean that drinking improved the children's outcome," the FASD Study Group said.

The published report looked at the drinking patterns of pregnant mothers of three-year-olds and assessed the behavior and cognitive skills of the children. The University College London researchers actually reported that the children born to women who drank lightly during pregnancy were not at increased risk compared with children of mothers who did not drink during pregnancy.

However, this result may be based on the higher socioeconomic status of the light drinking mothers and their children involved in this study. Higher socioeconomic status is well known to improve an infant's neurodevelopmental outcome. The study's authors, Dr. Yvonne Kelly at University College London and colleagues, suggested this explanation for their findings and the FASD Study Group agrees with that conclusion.

Many published reporters show that even moderate to light drinking can cause birth defects.

"Generally, the adverse effects of light drinking during pregnancy are subtle and may go undetected in children," said Feng Zhou, Ph.D., president of the FASD Study Group and a professor of
'/>"/>

Contact: Mary L. Hardin
mhardin@iupui.edu
317-274-7722
Indiana University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Pexiganan Phase 3 Clinical Trials Results Published in December Issue of CID
2. New Guidebook Published for Improving B2B Sales Results in 90 Days or Less Through Kaizen Events
3. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
4. New Requirements of EU Medical Device Directive Need Immediate Action, Nerac Analysts Urge in Newly Published White Paper
5. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
6. First Study of War-Related Mental Disorders Among Iraqis 10 Years Post-Gulf War Published by Researchers at Wayne State University and Basrah University, Iraq
7. Long-Term Results of VisionCares Implantable Telescope for End-Stage Macular Degeneration Published in the American Journal of Ophthalmology
8. Results From Pre-Election Surveys Published in NEJM Show Deep Concerns About State of Health Care With McCain and Obama Supporters Differing Sharply on Directions for New Administration
9. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
10. International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer
11. MultiVu Video Feed: NEW RESEARCH PUBLISHED IN THE AMERICAN JOURNAL OF CLINICAL NUTRITION FINDS PISTACHIOS IMPROVE RISK FACTORS FOR HEART DISEASE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Rancho Cucamonga, Ca (PRWEB) , ... July 06, 2015 , ... ... two distinguished awards in 2015, marking him as an attorney who has ... Fernando Vargas received both a Client Distinction Award for 2015 from Martindale-Hubbell and a ...
(Date:7/6/2015)... ... , ... University of Pittsburgh Cancer Institute (UPCI) scientists recently led ... newly available tests that better incorporate personalized medicine into diagnosing the condition. , ... is published in the July issue of the scientific journal Thyroid . ...
(Date:7/6/2015)... ... July 06, 2015 , ... Shortly after opening her ... the leading network of doctors working on a lien basis. Dr. Lim had ... , The daughter of two Cambodian refugees, Dr. Lim suffered with back pain herself ...
(Date:7/6/2015)... Virginia (PRWEB) , ... July 06, 2015 , ... ... choose fat-reduction procedures each year for aesthetic reasons, which is why liposuction regularly ... For a particular demographic, however, fat reduction has become more than a way ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... for radiology services and ADVOCATE is leading the transition. ADVOCATE, the only 100% ... with their Top 10 Tips for ICD-10. The ten tips are timely and ...
Breaking Medicine News(10 mins):Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2
... for Everyone , Not all patients can tolerate ... can help physicians calculate the epirubicin dose associated with ... , Oncologists frequently use anthracyclines, including epirubicin and doxorubicin, ... lasting heart problems in a substantial number of patients. ...
... 6.9 percent sequentially - Q2 GAAP net profit ... - Case shipments of 54,870 increase 6.0 percent sequentially ... SANTA CLARA, Calif., July 29 Align,Technology, Inc. (Nasdaq: ALGN ... ended June 30, 2008., Total net revenues for the second ...
... projected ... ... of,high-quality ceramic solutions for the medical device industry, announced,today that, in ... on unit shipments to the orthopaedic,brachytherapy and electro-implantable market segments., ...
... FACP, FACEP (E), Executive,Director, American Public Health Association, ... Association strongly urges U.S. House members to vote ... Food and Drug Administration (FDA),the authority to regulate ... for more than 400,000 deaths each,year and costs ...
... of matted protein, researchers say , , TUESDAY, July 29 (HealthDay ... clogging "tangles" in the brain cells of people with Alzheimer,s ... studies are necessary to confirm whether the medication is as ... needs to be given as part of a cocktail of ...
... ... Future Costs Can Be Avoided with Proper Treatment and Prevention ... Initiatives, NEW BRUNSWICK, N.J., ... on New,Jersey,s economy of the most common chronic diseases is calculated to be,$39 billion. In ...
Cached Medicine News:Health News:Also in the July 29 JNCI 2Health News:Also in the July 29 JNCI 3Health News:Also in the July 29 JNCI 4Health News:Also in the July 29 JNCI 5Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 2Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 3Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 4Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 5Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 6Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 7Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 8Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 9Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 10Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 11Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 12Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 13Health News:C5 Medical Werks Reaches Million Mark in Components Shipped 2Health News:'De-Tangling' Alzheimer's Drug Shows Promise 2Health News:'De-Tangling' Alzheimer's Drug Shows Promise 3Health News:'De-Tangling' Alzheimer's Drug Shows Promise 4Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 2Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 3Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 4
(Date:7/6/2015)... Moerae Matrix, a clinical stage biotechnology ... inflammation and fibrosis, today announced the appointment of ... Medical Officer. Dr. Bradford will ... which include a pipeline of therapies for pulmonary ... is an accomplished strategist and scientist with extensive ...
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... --  Cepheid (Nasdaq: CPHD ) today announced that ... quarter ended June 30, 2015 on Thursday, July 23, ... The Company will host a management presentation at 2 ... discuss the results.  To access the live webcast, please ... 15 minutes before the scheduled start time to download ...
Breaking Medicine Technology:Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
... 2011 VolitionRX Limited ("Volition") (VNRX.OB), ... diagnostic tests, is pleased to announce that its ... signed a contract which is expected to provide ... commissioned to develop epigenetic profiling signatures from blood. ...
... Technology Services successfully implemented advanced process technology for ... in Shanghai, China, using Intergraph® integrated design and ... solvent and energy consumption as well as operating ... http://photos.prnewswire.com/prnh/20081211/DECLOGO) These results are achieved, among ...
Cached Medicine Technology:VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures 2VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures 3Intergraph® Technology Enables Bayer Technology Services to Engineer New Plant in China 2Intergraph® Technology Enables Bayer Technology Services to Engineer New Plant in China 3
Inquire...
Superior imaging through a 410,000 pixel CCD, unseen color replication from a digital signal processor in the scope, and the added benefit of four way tip deflection make the TF410 a superior choice ...
The computer-optimized optical design produces large, brilliant images of high resolution....
ACMI™ Distortion-Free Laparoscopes utilize technical advances in optical lens design to provide images without the fish-eye effect typically found on the peripheral viewing edges of conventional...
Medicine Products: